

Second Opinion: Urologic Oncology Investigators Discuss How They Apply Clinical Research in the Care of Patients with Urothelial Bladder Cancer**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Which of the following therapies is designated as an NCCN® (National Comprehensive Cancer Network®) preferred regimen for the first-line treatment of metastatic urothelial bladder cancer (UBC) in a patient who is not eligible for cisplatin-based therapy?**
 - Gemcitabine/nivolumab
 - b. Enfortumab vedotin/pembrolizumab**
 - Atezolizumab
 - Avelumab
 - None of the above
- 2. Which of the following therapies is FDA approved for patients with previously treated HER2-overexpressing advanced UBC?**
 - Tucatinib/trastuzumab
 - b. Trastuzumab deruxtecan**
 - Neratinib
 - Disitamab vedotin
 - None of the above: HER2-targeted therapy is not approved for UBC
- 3. Which of the following serious adverse events is most commonly associated with trastuzumab deruxtecan?**
 - Cytokine release syndrome
 - Tumor lysis syndrome
 - Hearing loss
 - d. Interstitial lung disease**
- 4. What was the approximate reduction in the risk of mortality for patients with previously untreated advanced UBC who received enfortumab vedotin with pembrolizumab in the Phase III EV-302/KEYNOTE-A39 study?**
 - 5%
 - 25%
 - c. 55%**
 - 85%
- 5. Approximately what proportion of cases of bladder cancer harbor a form of HER2 alteration?**
 - 10%
 - b. 30%**
 - 50%
 - 70%
 - 90%